Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
Journal of Rheumatology
2022
|